Systemic corticosteroids in vitiligo: Evidence-based insights and practical considerations

INTRODUCTION

Vitiligo is a chronic, acquired pigmentary disorder that affects approximately 0.5–2% of the global population, characterized by the selective destruction of melanocytes resulting in well-demarcated depigmented macules and patches on the skin and mucous membranes. Although it is a benign condition, vitiligo carries substantial psychosocial burdens, particularly in dark-skinned populations, due to the stark cosmetic disfigurement and social stigma associated with its appearance.^[1]

The pathogenesis of vitiligo is multifactorial, with autoimmune, oxidative stress, neural, and genetic components contributing to melanocyte destruction. The autoimmune hypothesis remains the most widely accepted, supported by the presence of melanocyte-specific antibodies and T-cell infiltration in vitiliginous lesions.^[2] This immunological basis has informed the rationale for using immunomodulatory agents, including corticosteroids, as part of therapeutic interventions in vitiligo.

While topical corticosteroids and calcineurin inhibitors are the mainstay for localized disease, systemic therapies become indispensable in cases of rapidly spreading or extensive vitiligo, where the aim is to arrest disease progression and induce repigmentation. Systemic corticosteroids, particularly when administered in carefully tailored pulse regimens, have been found to be effective in stabilizing disease activity, especially during the early inflammatory phase.^[3]

Despite their efficacy, systemic corticosteroids pose a challenge in dermatologic practice due to their well-documented adverse effect profile, including metabolic, psychiatric, and bone-related complications. However, the advent of oral mini-pulse (OMP) therapy and intermittent dosing protocols has mitigated some of these risks, enabling their safer use in dermatologic contexts.^[4]

Over the past two decades, a growing body of evidence has explored the use of systemic corticosteroids in vitiligo, evaluating various agents (e.g., dexamethasone, betamethasone, and prednisolone), regimens (daily vs. pulse), dosages, and combinations with phototherapy or other immunomodulators. Nevertheless, clinical consensus regarding optimal treatment protocols and long-term safety remains limited, particularly in special populations such as children, pregnant women, and the elderly.^[5]

This review aims to provide a comprehensive, evidence-based synthesis of current knowledge regarding systemic corticosteroids in the treatment of vitiligo. We summarize the mechanistic rationale, clinical protocols, efficacy outcomes, adverse effects, and practical considerations, with the goal of guiding clinicians in optimizing therapeutic strategies while balancing safety and efficacy.

METHODOLOGY

This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [Figure 1]. A comprehensive literature search was performed using four major databases: PubMed, Scopus, Web of Science, and the Cochrane Library, covering studies published from January 2000 to June 2025. The final search was conducted in July 2025.

Close

Figure 1:

Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow diagram.

Export to PPT

The following keywords and MeSH terms were used in various Boolean combinations: “vitiligo,” “systemic corticosteroids,” “oral corticosteroids,” “pulse therapy,” “dexamethasone,” “betamethasone,” “OMP,” “immunosuppression,” and “repigmentation.”

PATHOGENESIS OF VITILIGO AND RATIONALE FOR CORTICOSTEROID USE

Vitiligo is widely recognized as a complex autoimmune skin disorder characterized by the progressive destruction of epidermal melanocytes. Although the exact etiology remains incompletely understood, multiple interrelated mechanisms have been implicated in disease initiation and propagation, including autoimmunity, oxidative stress, genetic predisposition, neurogenic factors, and intrinsic melanocyte abnormalities.^[6]

TYPES AND REGIMENS OF SYSTEMIC CORTICOSTEROID THERAPY IN VITILIGO

Systemic corticosteroids have emerged as a key therapeutic option for active, progressive vitiligo, with various regimens tailored to balance efficacy and safety. The principal strategies include daily oral administration and pulse therapy, particularly OMP regimens. Each protocol has unique pharmacologic considerations, dosing schedules, and risk profiles.

SAFETY PROFILE AND ADVERSE EFFECTS

The systemic use of corticosteroids in vitiligo is generally considered safe when employed in judiciously selected patients and under careful medical supervision. This is particularly true for low-dose or OMP regimens, which have shown a favorable balance between efficacy and tolerability. Nonetheless, corticosteroids are not without risk, and clinicians must remain vigilant for adverse effects that may arise even at lower or intermittent dosing schedules.^[23]

Commonly reported side effects in patients receiving corticosteroids for vitiligo include weight gain, moon facies, acneiform eruptions, and mild gastrointestinal disturbances such as gastritis or dyspepsia. In a prospective study by Majid, 12% of patients developed noticeable weight gain, while 9% reported gastritis and 5% experienced acne.^[18] Fortunately, these effects were generally mild and reversible on dose reduction or discontinuation of therapy. Facial puffiness and menstrual irregularities, particularly in women of reproductive age, are also observed with systemic corticosteroid use, alongside mood disturbances such as irritability, anxiety, or insomnia, which tend to resolve after treatment cessation.^[18]

Corticosteroids also impact endocrine and metabolic function, including glucose metabolism and bone homeostasis. In some patients, especially those receiving daily regimens or higher cumulative doses, hyperglycemia or dyslipidemia may be observed, warranting periodic fasting glucose and lipid profile monitoring. Prolonged corticosteroid exposure can lead to reduced bone mineral density, increasing the risk for osteopenia or osteoporosis. Calcium and Vitamin D supplementation, along with weight-bearing exercise, may be recommended for patients on extended therapy. Although HPA axis suppression is uncommon with OMP therapy, it remains a theoretical risk, particularly in regimens extending beyond 3–6 months, and may necessitate morning cortisol monitoring if clinical suspicion arises.^[21]

In pediatric patients, systemic corticosteroids raise additional concerns. The potential for growth suppression, delayed puberty, and behavioral changes such as hyperactivity or mood lability requires careful dosing, close clinical follow-up, and clear communication with families. Nevertheless, OMP regimens using dexamethasone at 0.1 mg/kg twice weekly have demonstrated a reasonable safety profile and can be effective in arresting rapidly progressive vitiligo in children. Growth chart monitoring and psychosocial support are essential components of pediatric care.^[9]

Psychiatric and neurologic adverse effects, while less common, may include steroid-induced mood swings, anxiety, or, in rare cases, psychosis. These effects are more likely with higher or prolonged dosing but may occur even at low doses in predisposed individuals. Patients with a personal or family history of psychiatric illness should be screened before initiation, and early warning signs should prompt dose adjustment or discontinuation.^[11]

Absolute contraindications to systemic corticosteroid use include active systemic infections such as tuberculosis, uncontrolled diabetes mellitus, peptic ulcer disease, and hypersensitivity to corticosteroids. Relative contraindications include hypertension, glaucoma, osteoporosis, and a known history of psychiatric illness. As a precaution, baseline investigations including blood pressure, fasting blood glucose, and liver function tests should be obtained before starting therapy.^[4]

Finally, appropriate tapering of systemic corticosteroids is essential to avoid both disease flare-up and the risk of adrenal insufficiency. Abrupt cessation, especially after prolonged therapy, may provoke rebound depigmentation or systemic symptoms. Tapering schedules should be individualized based on the initial dose and duration of treatment; in OMP protocols, gradual reduction over 4–6 weeks is generally well tolerated.

SPECIAL POPULATIONS: PEDIATRIC, PREGNANT, AND ELDERLY PATIENTS

The therapeutic use of systemic corticosteroids in vitiligo requires nuanced consideration in special populations, particularly pediatric patients, pregnant or lactating women, and elderly individuals. Each group presents unique physiological and safety challenges that must be addressed to ensure effective and safe treatment.^[23]

In pediatric patients, vitiligo can have a profound psychological and social impact, especially when it affects visible areas such as the face or hands. Systemic corticosteroids may be indicated in rapidly progressive or unstable vitiligo when topical therapies fail or are impractical due to extensive involvement. However, children are more susceptible to corticosteroid-related adverse effects, including growth suppression, delayed pubertal development, and behavioral disturbances. OMP therapy, particularly using dexamethasone at 0.1 mg/kg on 2 non-consecutive days/week, has shown favorable outcomes in arresting disease progression with a relatively low incidence of adverse effects. Clinical monitoring should include growth velocity assessments, pubertal staging, and periodic evaluation for metabolic disturbances. Parental counseling is critical to ensure adherence and to address concerns about long-term safety.^[25]

Pregnancy presents a more complex scenario. The use of systemic corticosteroids during pregnancy is generally reserved for refractory or severe cases of vitiligo and should only be considered when the potential benefits outweigh the risks to the fetus. Although corticosteroids such as prednisone are considered relatively safe in pregnancy due to their inactivation by placental enzymes, there remains a small but documented risk of orofacial clefts, low birth weight, and maternal complications such as gestational diabetes and hypertension. Low-dose, short-duration regimens are preferred, and topical alternatives should be exhausted before initiating systemic therapy. During lactation, systemic corticosteroids can be used with caution. Studies have shown that low-dose prednisone or dexamethasone yields minimal transfer into breast milk and is unlikely to cause harm to the infant. However, feeding should ideally be delayed by 3–4 h after dose ingestion to minimize exposure.^[24,26]

In the elderly, the approach to systemic corticosteroid therapy must account for age-related physiological decline and the higher baseline prevalence of comorbidities such as hypertension, diabetes, osteoporosis, and cardiovascular disease. These factors increase the risk of corticosteroid-induced complications, including fluid retention, glucose intolerance, and bone demineralization. Therefore, the threshold for initiating systemic therapy in elderly patients is higher, and the treatment duration should be as short as possible with close monitoring. Dose adjustments may be necessary based on renal and hepatic function. Bone density assessment, regular blood pressure checks, and fall risk evaluations are prudent measures to mitigate complications.^[27,28]

Overall, systemic corticosteroids can be used in special populations with careful risk-benefit assessment, appropriate dose modifications, and vigilant follow-up. Multidisciplinary collaboration – particularly with pediatricians, obstetricians, and geriatricians – can enhance treatment safety and optimize outcomes in these vulnerable groups. Summary table of some included studies of systemic corticosteroids in vitillgo [Table 2].

COMBINATION THERAPIES AND ADJUNCTIVE OPTIONS

The management of vitiligo, particularly in its progressive or extensive forms, often necessitates a multimodal therapeutic strategy. While systemic corticosteroids are effective in halting disease progression, their combination with other treatment modalities can enhance repigmentation outcomes, reduce corticosteroid dosage, and minimize adverse effects. Increasingly, clinicians are adopting combination approaches to achieve better disease control and cosmetic improvement.^[2]

One of the most commonly employed adjuncts to systemic corticosteroid therapy is NB-UVB phototherapy. The immunomodulatory and melanocyte-stimulating properties of NB-UVB make it an ideal complement to corticosteroids. When used concurrently, systemic corticosteroids suppress the inflammatory process responsible for melanocyte destruction, while NB-UVB promotes melanocyte proliferation and migration from hair follicles. This synergistic effect has been supported by several clinical trials. For example, a randomized controlled trial demonstrated that the combination of OMP dexamethasone and NBUVB phototherapy led to superior repigmentation rates and earlier disease stabilization compared to either treatment alone.^[31]

Topical therapies are also frequently used alongside systemic corticosteroids to enhance local efficacy and reduce the systemic dose burden. Topical corticosteroids, calcineurin inhibitors (such as tacrolimus or pimecrolimus), and Vitamin D analogs may be applied to localized lesions while systemic corticosteroids address widespread activity. This approach is particularly valuable in facial or genital vitiligo, where systemic treatment may be excessive, yet local immune modulation is still required. A split-body study using systemic steroids and topical tacrolimus on one side versus steroids alone on the other showed better repigmentation in the combined treatment group, highlighting the potential of localized adjuncts.^[32]

In select cases, antioxidants such as Vitamins C and E, alpha-lipoic acid, and ginkgo biloba have been used as supportive therapy to mitigate oxidative stress, a known contributor to melanocyte apoptosis in vitiligo. Although evidence remains preliminary, these agents may support overall treatment goals when used in conjunction with systemic corticosteroids. Similarly, zinc and folic acid supplementation has been explored, particularly in patients with confirmed deficiencies or as part of holistic care models.

Recent advancements have also introduced the possibility of using Janus kinase (JAK) inhibitors, both topical and systemic, in refractory vitiligo. Although not yet standard care, their immunosuppressive mechanisms offer potential synergy with corticosteroids, especially in difficult-to-treat cases. However, data on their combined use are limited, and safety concerns necessitate caution.^[33]

In children or patients reluctant to use phototherapy, systemic corticosteroids may be combined with herbal or traditional medicine under supervision, though robust evidence for these combinations remains sparse. It is critical to evaluate each adjunctive therapy for potential interactions, cumulative toxicity, and patient-specific contraindications.^[34]

Ultimately, combination therapy in vitiligo should be tailored based on disease extent, activity level, age, comorbidities, and patient preferences. The strategic use of corticosteroids with adjunctive treatments holds promise for achieving optimal outcomes with fewer side effects, making individualized multimodal therapy the cornerstone of modern vitiligo management.

GUIDELINES AND CONSENSUS STATEMENTS ON SYSTEMIC CORTICOSTEROID USE IN VITILIGO

Systemic corticosteroids are primarily reserved for patients with rapidly progressive vitiligo, where they are used to arrest disease activity rather than to induce repigmentation. The International Vitiligo Task Force, in its 2023 global position statement, recommends the OMP regimen with dexamethasone 2.5–5 mg or betamethasone 5 mg on 2 consecutive days/week for a minimum of 3 months, extendable to 6 months if needed, while discouraging long-term continuous dosing. The task force also strongly advises combining systemic corticosteroids with narrowband UVB phototherapy for optimal disease control.^[35]

The British Association of Dermatologists (BAD) 2021 guideline likewise restricts systemic corticosteroids to patients with rapidly spreading vitiligo. It recommends oral betamethasone at approximately 0.1 mg/kg (commonly 5 mg) twice weekly on 2 consecutive days, administered for 3 months, followed by a taper over subsequent months. The BAD explicitly cautions against prolonged daily corticosteroid regimens due to the risk of systemic adverse effects and advocates concurrent use of NB-UVB phototherapy.^[36]

The European Dermatology Forum and Vitiligo European Task Force consensus also supports OMP regimens in active vitiligo, highlighting their role in halting progression. Short-term daily prednisolone at 0.3 mg/kg/day may be considered in selected cases, although pulsed regimens are favored for improved safety. The consensus emphasizes that systemic corticosteroids should rarely be used in isolation, but rather as part of combination therapy strategies with phototherapy and topical agents.^[37]

In the United States, the American Academy of Dermatology (AAD) acknowledges systemic corticosteroids as an option for patients with new or rapidly progressive vitiligo but provides less detailed dosing protocols compared with European and Indian recommendations. The AAD stresses that systemic therapy should be used only as short courses, usually not exceeding 3 months, and should not be continued long-term due to metabolic, skeletal, and psychiatric risks.^[38]

The Indian Association of Dermatologists, Venereologists, and Leprologists (IADVL) consensus statement is one of the most detailed in terms of systemic corticosteroid protocols. It recommends either low-dose daily prednisolone (around 0.3 mg/kg/day for 1–3 months with tapering) or OMP regimens using dexamethasone 2.5–5 mg or methylprednisolone 32 mg on 2 consecutive days/week for 3–6 months. These regimens have been supported by multiple Indian case series and clinical studies showing effective disease stabilization with relatively few adverse effects. The IADVL strongly advises regular monitoring for systemic complications and generally recommends concomitant NBUVB phototherapy as the standard of care.^[39,40]

The Japanese Dermatological Association (2013 guidelines) also recognizes systemic corticosteroids for rapidly progressive disease, with OMP or pulse regimens used cautiously. In some refractory cases, intravenous methylprednisolone pulse therapy (e.g., 500 mg daily for 3 consecutive days monthly) has been reported, though this remains less standardized. Japanese guidelines emphasize individualizing therapy by age and comorbidity, with special caution in pediatric and elderly patients.^[41]

The German S1 guideline (2022) similarly restricts systemic corticosteroids to short-term use in selected cases of active vitiligo. Both OMP and short daily regimens are considered acceptable, but the guideline prioritizes topical and phototherapy options where feasible. It underscores the risks of systemic adverse effects, particularly metabolic syndrome, and stresses structured monitoring and early transition to safer long-term modalities.^[42]

Overall, despite regional variations in dosing, all major international, American, European, Indian, Japanese, and German guidelines converge on the principle that systemic corticosteroids are useful only in short-term regimens for rapidly progressive vitiligo, preferably as OMP schedules for 3–6 months, almost always in combination with phototherapy, and never as long-term maintenance monotherapy [Table 3].

LIMITATIONS OF CURRENT EVIDENCE AND FUTURE DIRECTIONS

Despite the widespread use of systemic corticosteroids in vitiligo management and their inclusion in numerous treatment guidelines, several limitations in the current body of evidence hinder the formulation of universally standardized protocols. These limitations relate to both the quality and quantity of data, as well as the lack of long-term studies assessing efficacy, safety, and relapse rates.

One of the most pressing challenges is the heterogeneity in study design across available clinical trials and observational studies. Many studies exploring the efficacy of systemic corticosteroids – particularly OMP regimens – suffer from small sample sizes, lack of blinding, or inadequate control groups. As a result, comparison across studies is difficult, and meta-analyses often face issues related to data pooling and bias. In addition, standardized outcome measures such as the vitiligo disease activity score, vitiligo area scoring index, or patient-reported quality of life indices are inconsistently applied, making objective comparison of results challenging.

Another limitation lies in the underrepresentation of certain patient populations in clinical trials, including children, pregnant women, and the elderly. These groups are often excluded due to ethical or safety concerns, leaving clinicians to rely on anecdotal evidence or extrapolated data. Furthermore, there is limited research on how comorbid autoimmune or metabolic conditions may influence corticosteroid efficacy or safety in vitiligo, despite these being common in affected individuals.

Long-term safety data on systemic corticosteroids in vitiligo are sparse. Most studies focus on short-term endpoints such as disease stabilization and initial repigmentation, without adequate follow-up to assess relapse rates or adverse effects after discontinuation. Given the well-known complications of corticosteroids – including metabolic, endocrine, musculoskeletal, and psychological effects – future research must extend observation periods to better understand the risk-benefit profile of such therapies over time.

There is also an unmet need for comparative studies that assess corticosteroids against newer therapeutic agents such as JAK inhibitors, biologics, or emerging small molecules. As the treatment landscape for vitiligo continues to evolve, systemic corticosteroids will need to be evaluated not only in isolation but also in the context of multimodal and personalized treatment approaches. Trials exploring head-to-head comparisons or combination regimens could provide more practical insights into optimizing treatment sequences and combinations.

From a mechanistic standpoint, additional research is needed to elucidate precisely how systemic corticosteroids modulate the immune environment in vitiligo, particularly at the molecular level. The emerging understanding of the disease as a complex neuro-immuno-cutaneous disorder involving T-cell dysregulation, oxidative stress, and neural peptides suggests multiple potential targets beyond glucocorticoid pathways. Advanced imaging, transcriptomic profiling, and biomarker studies could help refine patient stratification and predict treatment response.

Finally, despite being a global condition, most data come from specific geographic regions (e.g., South Asia) and may not generalize across diverse populations with different genetic, environmental, or cultural backgrounds. This geographic bias limits the external validity of findings and underscores the need for international, multicenter collaborations.

In summary, while systemic corticosteroids remain a cornerstone in the management of progressive vitiligo, significant evidence gaps persist. Future research should aim for rigorous, multicenter, long-term trials with standardized protocols and broader patient inclusion to optimize and personalize corticosteroid therapy in vitiligo.

CONCLUSION

Systemic corticosteroids have long held a pivotal role in the management of vitiligo, particularly in cases characterized by rapid progression, widespread involvement, or significant psychosocial impact. Their immunosuppressive and anti-inflammatory properties allow for disease stabilization and, in many cases, facilitate repigmentation when used appropriately. Among various regimens, OMP therapy with dexamethasone or betamethasone remains the most studied and preferred method due to its favorable balance of efficacy and safety, especially in halting disease activity with fewer systemic side effects [Figure 2].

Close

Figure 2:

Summary of systemic corticosteroid in vitiligo.

Export to PPT

Despite their clinical utility, the use of systemic corticosteroids must be carefully tailored to individual patient profiles, considering factors such as age, comorbidities, disease duration, and psychosocial burden. In special populations – namely, pediatric, pregnant, and elderly patients – risk-benefit assessments and close monitoring are paramount. Adjunctive strategies, including combination with phototherapy or topical agents, have shown synergistic effects and may enhance treatment outcomes while minimizing corticosteroid exposure.

Current guidelines and consensus statements reflect the value of systemic corticosteroids in vitiligo, yet also highlight the need for restraint, emphasizing short durations, dose minimization, and close clinical follow-up. However, limitations in existing evidence, such as small sample sizes, inconsistent methodologies, and a lack of long-term data, present significant challenges in standardizing care. Moreover, with the advent of novel therapies like JAK inhibitors and targeted biologics, corticosteroids must now be considered as part of an evolving therapeutic paradigm rather than a standalone solution.

Future research should aim to fill existing knowledge gaps through well-designed, multicenter randomized trials, with particular attention to long-term safety, relapse rates, and optimal combination strategies. Advances in understanding the immunopathogenesis of vitiligo may eventually guide more targeted use of corticosteroids or entirely new classes of therapeutics. Until then, systemic corticosteroids remain a valuable option when used judiciously and within the framework of evidence-based, patient-centered care.